JP2004525950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525950A5 JP2004525950A5 JP2002579013A JP2002579013A JP2004525950A5 JP 2004525950 A5 JP2004525950 A5 JP 2004525950A5 JP 2002579013 A JP2002579013 A JP 2002579013A JP 2002579013 A JP2002579013 A JP 2002579013A JP 2004525950 A5 JP2004525950 A5 JP 2004525950A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- rapamycin
- tumor
- use according
- mtor inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 18
- 229960002930 sirolimus Drugs 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 12
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 10
- 230000000340 anti-metabolite Effects 0.000 claims 9
- 239000002256 antimetabolite Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- HKVAMNSJSFKALM-SQMKDCFHSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-SQMKDCFHSA-N 0.000 claims 3
- 229960002949 Fluorouracil Drugs 0.000 claims 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 3
- 201000011231 colorectal cancer Diseases 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 206010073145 Soft tissue cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical group C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 230000000259 anti-tumor Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Claims (31)
- mTORインヒビターおよび代謝拮抗性抗腫瘍剤の少なくとも一つの医薬の製造における使用であって、その少なくとも一つの医薬が哺乳動物における腫瘍を治療するためのmTORインヒビターおよび代謝拮抗性抗腫瘍剤のデリバリーにより特徴付けられる組み合わせにて投与可能であるところの、使用。
- mTORインヒビター、代謝拮抗物質のいずれかまたは両方を治療量以下の有効量でデリバリーする、請求項1記載の使用。
- mTORインヒビターを治療量以下の有効量でデリバリーする、請求項1または2記載の使用。
- 代謝拮抗物質を治療量以下の有効量でデリバリーする、請求項1ないし3のいずれか1項記載の方法。
- 腫瘍が、腎臓癌、柔組織癌、乳癌、肺の神経内分泌腫瘍、子宮頚癌、膀胱癌、頭部ならびに頚部癌、神経膠腫、非小肺細胞癌、前立腺癌、膵臓癌、リンパ腫、黒色腫、小細胞肺癌、卵巣癌、結腸癌、食道癌、胃癌、白血病、結腸直腸癌、および未知の一次癌の一つである、請求項1〜4のいずれか1項記載の使用。
- 組み合わせが生化学的変更剤をさらに含む、請求項1〜5のいずれか1項記載の使用。
- 生化学的変更剤がロイコボリンまたはレボホリネートである、請求項6記載の使用。
- 代謝拮抗物質がゲムシタビンである、請求項1〜7のいずれか1項記載の使用。
- 腫瘍が膵臓癌である、請求項1〜8のいずれか1項記載の使用。
- 代謝拮抗物質が5−フルオロウラシルである、請求項1〜7のいずれか1項記載の使用。
- 組み合わせが生化学的変更剤をさらに含む、請求項1〜10のいずれか1項記載の使用。
- 該組み合わせがmTORインヒビター、5−フルオロウラシル、およびロイコボリンの組み合わせを含む、請求項1〜5のいずれか1項記載の使用。
- 腫瘍が結腸直腸癌である、請求項10〜12のいずれか1項記載の使用。
- mTORインヒビターがラパマイシンである、請求項1〜13のいずれか1項記載の使用。
- ラパマイシンがラパマイシンである、請求項14記載の使用。
- ラパマイシンが42−O−(2−ヒドロキシ)エチルラパマイシンである、請求項14記載の使用。
- ラパマイシンが3−ヒドロキシ−2−(ヒドロキシメチル)−2−メチルプロピオン酸とのラパマイシン42−エステルである、請求項14記載の使用。
- mTORインヒビターと代謝拮抗性抗腫瘍剤の有効量を含む、抗腫瘍組み合わせ。
- 生化学的変更剤をさらに含む、請求項18記載の組み合わせ。
- mTORインヒビターがラパマイシンである、請求項19記載の組み合わせ。
- ラパマイシンがラパマイシンである、請求項19記載の組み合わせ。
- ラパマイシンが42−O−(2−ヒドロキシ)エチルラパマイシンである、請求項19記載の組み合わせ。
- ラパマイシンが3−ヒドロキシ−2−(ヒドロキシメチル)−2−メチルプロピオン酸とのラパマイシン42−エステルである、請求項19記載の組み合わせ。
- 哺乳動物における腫瘍の治療における、同時、別個、または連続使用のための組み合わせ製剤としての、mTORインヒビターおよび代謝拮抗性抗腫瘍剤を含む製品。
- 生化学的変更剤をさらに含む、請求項24記載の製品。
- 腫瘍が、腎臓癌、柔組織癌、乳癌、肺の神経内分泌腫瘍、子宮頚癌、膀胱癌、頭部ならびに頚部癌、神経膠腫、非小肺細胞癌、前立腺癌、膵臓癌、リンパ腫、黒色腫、小細胞肺癌、卵巣癌、結腸癌、食道癌、胃癌、白血病、結腸直腸癌、および未知の一次癌の一つである、請求項24または請求項25記載の製品。
- mTORインヒビターがラパマイシンである、請求項24〜26のいずれか1項記載の製品。
- ラパマイシンがラパマイシンである、請求項27記載の製品。
- ラパマイシンが42−O−(2−ヒドロキシ)エチルラパマイシンである、請求項27記載の製品。
- ラパマイシンが3−ヒドロキシ−2−(ヒドロキシメチル)−2−メチルプロピオン酸とのラパマイシン42−エステルである、請求項27記載の製品。
- 代謝拮抗物質がゲムシタビンまたは5−フルオロウラシルである、請求項24〜30のいずれか1項記載の製品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28238801P | 2001-04-06 | 2001-04-06 | |
US28238501P | 2001-04-06 | 2001-04-06 | |
PCT/US2002/010912 WO2002080975A1 (en) | 2001-04-06 | 2002-04-05 | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004525950A JP2004525950A (ja) | 2004-08-26 |
JP2004525950A5 true JP2004525950A5 (ja) | 2005-12-22 |
Family
ID=26961412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002579013A Pending JP2004525950A (ja) | 2001-04-06 | 2002-04-05 | ラパマイシンとゲムシタビンまたはフルオロウラシルなどの、抗腫瘍剤の組み合わせ |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1385551B1 (ja) |
JP (1) | JP2004525950A (ja) |
KR (1) | KR100862178B1 (ja) |
CN (1) | CN1309421C (ja) |
AT (1) | ATE406892T1 (ja) |
AU (1) | AU2007242958A1 (ja) |
BR (1) | BR0208627A (ja) |
CA (1) | CA2442849A1 (ja) |
DE (1) | DE60228699D1 (ja) |
EA (1) | EA010184B1 (ja) |
ES (1) | ES2312568T3 (ja) |
HK (1) | HK1060062A1 (ja) |
HU (1) | HUP0304093A3 (ja) |
IL (1) | IL157898A0 (ja) |
MX (1) | MXPA03009092A (ja) |
NO (1) | NO20034433L (ja) |
NZ (1) | NZ540047A (ja) |
PL (1) | PL363991A1 (ja) |
PT (1) | PT1385551E (ja) |
SG (1) | SG152906A1 (ja) |
SI (1) | SI1385551T1 (ja) |
WO (1) | WO2002080975A1 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60134679D1 (de) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
ES2728739T3 (es) * | 2001-02-19 | 2019-10-28 | Novartis Pharma Ag | Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada |
GB0124577D0 (en) * | 2001-10-12 | 2001-12-05 | Novartis Forschungsstiftung | Novel methods |
EP2407473A3 (en) | 2002-02-01 | 2012-03-21 | ARIAD Pharmaceuticals, Inc | Method for producing phosphorus-containing compounds |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
WO2005082397A1 (en) * | 2004-02-26 | 2005-09-09 | The Penn State Research Foundation | Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
WO2006027545A2 (en) * | 2004-09-10 | 2006-03-16 | Agency For Science, Technology And Research | Method |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
WO2006084058A2 (en) | 2005-02-03 | 2006-08-10 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
WO2007056118A1 (en) * | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
CN102579467A (zh) * | 2005-11-14 | 2012-07-18 | 阿里亚德医药股份有限公司 | 雷帕霉素衍生物在治疗癌症中的用途 |
GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
KR20080071600A (ko) * | 2005-11-21 | 2008-08-04 | 노파르티스 아게 | Mtor 억제제를 사용하는 신경내분비 종양 치료법 |
EP1880723A1 (en) * | 2006-07-14 | 2008-01-23 | Novartis AG | Combination of mTOR inhibitor and antifolate compound |
KR20080085213A (ko) * | 2006-01-12 | 2008-09-23 | 노파르티스 아게 | Mtor 억제제 및 항엽산 화합물의 조합물 |
US7651687B2 (en) | 2006-03-13 | 2010-01-26 | Osi Pharmaceuticals, Inc. | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
CA2645633A1 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
ES2556173T3 (es) | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
US20090311249A1 (en) * | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
WO2008016633A2 (en) * | 2006-08-02 | 2008-02-07 | Ariad Gene Therapeutics, Inc. | Combination therapy |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
WO2008044068A2 (en) * | 2006-10-11 | 2008-04-17 | Fusion Antibodies Limited | Combination therapy |
EP2094241A4 (en) | 2006-11-14 | 2013-04-17 | Ariad Pharma Inc | ORAL FORMULATIONS |
CN101616671A (zh) | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
PT2481409T (pt) * | 2007-03-07 | 2018-10-18 | Abraxis Bioscience Llc | Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno |
CA2689914C (en) | 2007-06-01 | 2016-08-16 | Abraxis Bioscience, Llc | Use of protein-bound taxane nanoparticles in the treatment of recurrent gynecological cancers |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
US8685995B2 (en) | 2008-03-21 | 2014-04-01 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
ES2614912T3 (es) | 2008-08-04 | 2017-06-02 | Wyeth Llc | Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina |
EP3000467B1 (en) | 2009-04-06 | 2023-03-01 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
KR102204279B1 (ko) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지 |
RS63559B1 (sr) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | Derivat hinolina velike čistoće i postupak za njegovu proizvodnju |
PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
PT3436461T (pt) | 2016-03-28 | 2024-01-23 | Incyte Corp | Compostos de pirrolotriazina como inibidores de tam |
TWI832871B (zh) | 2018-06-29 | 2024-02-21 | 美商英塞特公司 | Axl/mer 抑制劑之調配物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
JP4352115B2 (ja) * | 1997-01-24 | 2009-10-28 | クラヴィス・ファルマ・アーエスアー | ゲムシタビン誘導体 |
TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
-
2002
- 2002-04-05 CN CNB028077490A patent/CN1309421C/zh not_active Expired - Fee Related
- 2002-04-05 PL PL02363991A patent/PL363991A1/xx unknown
- 2002-04-05 CA CA002442849A patent/CA2442849A1/en not_active Withdrawn
- 2002-04-05 WO PCT/US2002/010912 patent/WO2002080975A1/en active Application Filing
- 2002-04-05 AT AT02726710T patent/ATE406892T1/de not_active IP Right Cessation
- 2002-04-05 JP JP2002579013A patent/JP2004525950A/ja active Pending
- 2002-04-05 SI SI200230737T patent/SI1385551T1/sl unknown
- 2002-04-05 BR BR0208627-1A patent/BR0208627A/pt not_active IP Right Cessation
- 2002-04-05 MX MXPA03009092A patent/MXPA03009092A/es active IP Right Grant
- 2002-04-05 PT PT02726710T patent/PT1385551E/pt unknown
- 2002-04-05 NZ NZ540047A patent/NZ540047A/en unknown
- 2002-04-05 DE DE60228699T patent/DE60228699D1/de not_active Expired - Fee Related
- 2002-04-05 EA EA200301091A patent/EA010184B1/ru not_active IP Right Cessation
- 2002-04-05 HU HU0304093A patent/HUP0304093A3/hu unknown
- 2002-04-05 KR KR1020037013090A patent/KR100862178B1/ko not_active IP Right Cessation
- 2002-04-05 EP EP02726710A patent/EP1385551B1/en not_active Expired - Lifetime
- 2002-04-05 ES ES02726710T patent/ES2312568T3/es not_active Expired - Lifetime
- 2002-04-05 SG SG200506382-1A patent/SG152906A1/en unknown
- 2002-04-05 IL IL15789802A patent/IL157898A0/xx unknown
-
2003
- 2003-10-03 NO NO20034433A patent/NO20034433L/no not_active Application Discontinuation
-
2004
- 2004-04-30 HK HK04103071A patent/HK1060062A1/xx not_active IP Right Cessation
-
2007
- 2007-12-13 AU AU2007242958A patent/AU2007242958A1/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004525950A5 (ja) | ||
RU2019101632A (ru) | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента | |
JP2008524225A5 (ja) | ||
RU2007126978A (ru) | Комбинации терапевтических агентов для лечения рака | |
WO2004071436A3 (en) | The use of gcc ligands | |
HUP0401089A2 (hu) | CCI-779 és EKB-569 tartalmú daganatellenes kombinációk | |
RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
WO2005013800A3 (en) | Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity | |
JP2009513662A5 (ja) | ||
MY183404A (en) | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors | |
TW200407326A (en) | Pyrimido compounds having antiproliferative activity | |
RU2010117635A (ru) | Комбинированная химиотерапия | |
JP2006524246A5 (ja) | ||
Monga et al. | Surgical adjuvant therapy for colorectal cancer: current approaches and future directions | |
JP2005511597A5 (ja) | ||
WO2006027693A3 (en) | Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis | |
JP2005538129A5 (ja) | ||
JP2004532883A5 (ja) | ||
Waizenegger et al. | Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation | |
FI3773595T3 (fi) | Syöpälääkekoostumuksia yhdistelmähoitoon | |
Mukaida et al. | Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-FU, and VP-16 for advanced esophageal cancer | |
McCubrey et al. | Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies | |
RU2024101250A (ru) | Фармацевтические комбинации, содержащие ингибитор kras g12c, и варианты их применения для лечения видов рака | |
RU2007115511A (ru) | Способ комбинированного лечения местнораспространенного немелкоклеточного рака легкого | |
Thiagalingam | The road to precision cancer therapy-history and strategies. |